First Participant Will Enroll in A Phase 2, Open-Label, Randomized Comparative Effectiveness Study for MDMA-Assisted Therapy in U.S. Military Veterans with Chronic PTSD

MAPS is sponsoring a Phase 2, open-label protocol to study the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with PTSD at the James J. Peters Veterans Affairs (VA) Medical Center in Bronx, New York. The study site researchers are currently scheduled to enroll the first participant in early February 2022. The study will continue screening and enrollment after the first participant is fully enrolled. The study is expected to treat up to 60 participants over 2-3 years.